Court Reports Favorable Judgment in California Stem Cell Case
SUNRISE, FL – September, 1st, 2022 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, is…
Mark Borman appointed Chairman of the Board of USRM
SUNRISE, FL – March 9th, 2022 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions has…
USRM to Focus on Animal Health and Lead Pet-Care Innovation
SUNRISE, FL – Oct 18th, 2021 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions will…
US Stem Cell Inc Reports Legal Appeal Results and Company Direction
SUNRISE, FL – June. 8th, 2021 – U.S. Stem Cell, Inc. (OTC: USRM), a corporation that has historically focused on the regenerative medicine / cellular therapy industry specializing in physician…
Northstar Biotech and USRM BOD Members Reinvest in the Company
SUNRISE, FL – Feb 23, 2021 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based, and novel regenerative medicine solutions, is pleased to announce…
USRM Oral Argument in Appeal from FDA Enforcement Action
SUNRISE, FL – Jan 19, 2021 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based, and novel regenerative medicine solutions, is pleased to announce…
U.S. Stem Cell Confirms Date for Appeals Court Oral Arguments
SUNRISE, FL – Sep. 30, 2020 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based, and novel regenerative medicine solutions, is pleased to announce…
CEO Blog: A Summary of Recent Events
Dear Shareholders and Friends, Thank you for your continued interest and support in U.S. Stem Cell, Inc. In an effort to keep you updated on matters related to the Company,…
Corrected: USRM Posts Earnings for Second Quarter 2019
SUNRISE, FL – August 7, 2019 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today…
USRM Posts Earnings for Second Quarter 2019
SUNRISE, FL – August 7, 2019 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today…
USRM Posts Financial Results for First Quarter 2019
SUNRISE, FL – May 7, 2019 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today…
USRM Posts Increase in Revenue and Profit Margin for 2018
SUNRISE, FL – March 13, 2019 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today…